-New patents expand portfolio of next generation “PEGylation” technology for modifying drug
molecules for improved drug performance-

Research Triangle Park, NC – February 1, 2005 – NOBEX Corporation, a drug product
innovation and development company specializing in medicinal chemistry-based drug delivery,
today announced that it has been granted two new U.S. patents covering its polyethylene glycol
(PEG) and related “micro-alkylPEGylation” technology. NOBEX focuses its efforts on the
technology covered in these new patents to enable the conversion of injectible-only drugs into oral
drugs. With its global co-development partner Biocon, NOBEX is developing an oral insulin
product, a convenient tablet dose, for patients with diabetes.
As more peptide hormones are identified as potential drugs, particularly those for chronic diseases
of metabolism and the cardiovascular system, oral delivery in tablet form is the ideal method to
achieve patient convenience and compliance as well as provide new medical benefits in some cases.
The two new patents described below can enable or enhance the delivery of both peptide-based and
small organic molecules by oral delivery but also by other routes of administration including
injection, pulmonary and transdermal delivery.
U.S. Patent No. 6,815,530, entitled “Substantially monodispersed mixtures of polymers having
polyethylene glycol moieties” covers small molecular-weight (up to several hundred Daltons) PEG
polymers in which substantially all of the PEG molecules have the same molecular weight. The
patent covers such monodispersed PEG polymers as individual compositions of matter, as well as in
combination with other components such as the alkyl and fatty acid compounds that NOBEX uses
in its proprietary micro-alkylPEGylation technology for drug modification.
U.S. Patent No. 6,835,802, entitled “Methods of synthesizing substantially monodispersed mixtures
of polymers having polyethylene glycol moieties” covers synthetic methods for producing the
monodispersed PEG and micro-alkylPEG (“oligomer”) compositions.
“The proprietary technology developed by NOBEX enables the synthesis of small, pure molecular
weight polymers themselves and the resultant polymer-drug molecules, an advance that imparts
superior chemical and biological properties to the polymer-drug molecules,” said Christopher H.
Price, Ph.D., President & CEO of NOBEX. “In addition to providing significant new patent
coverage for the NOBEX product pipeline, we believe that the technology will be of licensing
interest to other companies using PEG-based polymers to modify their therapeutic molecules. We
have observed that even a single ethylene glycol unit difference in a pure polymer-modified drug
can yield significantly different biological performance. Furthermore, a polymer-modified drug of
single molecular weight simplifies manufacturing and chemical analyses and can also extend the
patent lives of covered compounds.”
PO Box 13940
617 Davis Drive, Suite 100
Research Triangle Park, NC 27709
Durham, NC 27709
“NOBEX’s focus is on the oral delivery opportunities of our amphiphilic oligomer technology,
however, one can envision many other uses which may capitalize on the unique properties it
provides,” commented Nnochiri Ekwuribe, Ph.D., Vice President of Chemistry Innovation for
NOBEX. “Companies seeking to develop uses of the micro-alkylPEG polymers to exploit their
solubility and ionic and nonionic surfactant properties (e.g., in pharmaceutical formulations,
prepared foods, skin products) will find value in this technology. Their small, monodispersed
molecular structure and chemical properties may also be useful in areas such as nanotechnology.”
For NOBEX, the modification of peptide drugs for oral delivery is accomplished by chemically
coupling the small, pure oligomers covered by the new patents (and other patents in the NOBEX
portfolio) to the peptide at one or more selected sites, creating a new, pure single molecular entity.
The oligomers are “amphiphilic”, that is, they have a highly water-soluble portion (the PEG
polymer) on one end and a highly lipid-soluble portion on the other end of a single structure. The
balance of water and lipid solubility provided by the different polymers changes the chemical and
biological properties of the drug. The results are improvements in characteristics such as increased
shelf stability, resistance to enzymes, absorption into the body from the GI tract, and lengthened
circulation time in the blood.
PEG polymers are well established in the biopharmaceutical industry for modifying the
pharmacology of large protein drug molecules that are administered by injection. Large molecular
weight (several 1,000 Daltons) PEG polymers are attached to the protein drug in random fashion
and at variable numbers of sites on each molecule. This approach provides well-documented
benefits to the pharmacokinetics and bioactivity of the PEG-modified drug administered by
injection. However, PEG-modified proteins are not suited for delivery by the oral route of
administration due to their very large size.
About NOBEX
NOBEX Corporation is a privately-held drug product innovation and development company that is
the pioneer in medicinal and polymer chemistry applied to peptide drugs to enable and optimize
their delivery by the oral route. NOBEX focuses on developing products for chronic indications in
the metabolic and cardiovascular therapeutic areas. The company has been based in the Research
Triangle Park in North Carolina since 1993. The company has several products in development,
including oral insulin for diabetes (with partner Biocon Ltd.) and oral B-type natriuretic peptide for
heart failure. For more information, visit www.nobexcorp.com.
For further information about NOBEX, please contact Christopher H. Price, CEO, NOBEX
Corporation at 919-474-0507 or cprice@nobexcorp.com.
# # #

Back to Portfolio News